Trump Administration Eases Access to Certain Peptide Drugs
The Trump administration, influenced by Health Secretary Robert F. Kennedy Jr., has eased access to unproven peptide drugs favored by the wellness industry. This decision, which allows specialty pharmacies to sell certain peptides without full FDA approval for safety and…
Houston, TX, October 28, 2026 —
The Trump administration has eased access to certain peptide drugs favored by the wellness industry, allowing specialty pharmacies to sell them without full Food and Drug Administration approval for safety and effectiveness.
The decision was influenced by Health Secretary Robert F. Kennedy Jr. and came despite opposition from FDA scientific staffers, according to the information provided. The specific peptides covered, the date the decision took effect and the details of how the policy will be implemented were not provided.
The change has drawn opposing arguments over the balance between access and safety. Critics warn that wider access to unproven drugs could pose risks to public health. Proponents say the policy supports patient choice and offers an alternative to products sold through unregulated black-market channels.
The information provided does not identify the critics or proponents, describe the evidence behind their positions, or specify what safety measures may apply to sales through specialty pharmacies. It also does not state whether the FDA’s scientific staffers formally issued a public assessment or explain the basis of their opposition.
The decision concerns access to certain peptides without full FDA approval for safety and effectiveness; the available details do not establish that the drugs have been found safe or effective. Further specifics about the scope of the policy, the products affected and any next steps were not provided.
Story summarized from the original created by Matthew Perrone, Associated Press on www.click2houston.com, see more information here.
